{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T04:41:22Z","timestamp":1773117682384,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ijrobp.2021.10.152","type":"journal-article","created":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T11:00:46Z","timestamp":1636455646000},"page":"890-900","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology Group"],"prefix":"10.1016","volume":"112","author":[{"given":"Rahul R.","family":"Parikh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kara M.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C.","family":"Hodgson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradford S.","family":"Hoppe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen M.","family":"McCarten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"Karolczuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinglin","family":"Pei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve Y.","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter D.","family":"Cole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2021.10.152_bib0001","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1200\/JCO.2012.45.3266","article-title":"Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: Final results of the multinational trial GPOH-HD95","volume":"31","author":"D\u00f6rffel","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.10.152_bib0002","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood-2008-10-184143","article-title":"A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: The results of P9425","volume":"114","author":"Schwartz","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2021.10.152_bib0003","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1200\/JCO.2011.41.1819","article-title":"Long-term results of CCG 5942: A randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma\u2014a report from the Children's Oncology Group","volume":"30","author":"Wolden","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.10.152_bib0004","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.semradonc.2007.02.009","article-title":"Pediatric hodgkin lymphoma: Maximizing efficacy and minimizing toxicity","volume":"17","author":"Hodgson","year":"2007","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2021.10.152_bib0005","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1182\/blood-2015-07-641035","article-title":"Hodgkin lymphoma in children and adolescents: Improving the therapeutic index","volume":"126","author":"Kelly","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2021.10.152_bib0006","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.prro.2014.05.003","article-title":"International Lymphoma Radiation Oncology Group. Implementation of contemporary radiation therapy planning concepts for pediatric Hodgkin lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group","volume":"5","author":"Hodgson","year":"2015","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2021.10.152_bib0007","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/bjh.16014","article-title":"Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children\u2019s Oncology Group","volume":"187","author":"Kelly","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ijrobp.2021.10.152_bib0008","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/pbc.25205","article-title":"Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory\/relapsed Hodgkin lymphoma, AHOD00P1: A Children's Oncology Group report","volume":"62","author":"Trippett","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ijrobp.2021.10.152_bib0009","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","article-title":"Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting","volume":"7","author":"Lister","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.10.152_bib0010","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.10.152_bib0011","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/bjh.16197","article-title":"Closing the survivorship gap in children and adolescents with Hodgkin lymphoma","volume":"187","author":"Castellino","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ijrobp.2021.10.152_bib0012","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1200\/JCO.19.00812","article-title":"Survival by race and ethnicity in pediatric and adolescent patients with hodgkin lymphoma: A Children's Oncology Group study","volume":"37","author":"Kahn","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.10.152_bib0013","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1200\/JCO.2009.26.0323","article-title":"Consolidation radiotherapy in patients with advanced Hodgkin's lymphoma: Survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519)","volume":"28","author":"Johnson","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.10.152_bib0014","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1200\/JCO.2012.43.4803","article-title":"Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: An intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)","volume":"31","author":"Gordon","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.10.152_bib0015","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): Final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","volume":"390","author":"Borchmann","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2021.10.152_bib0016","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1470-2045(18)30784-8","article-title":"PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): A randomised, multicentre, non-inferiority, phase 3 study","volume":"20","author":"Casasnovas","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2021.10.152_bib0017","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1200\/JCO.2013.52.5410","article-title":"Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: A report from the Children's Oncology Group Study AHOD0031","volume":"32","author":"Friedman","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.10.152_bib0018","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ijrobp.2014.10.042","article-title":"Patterns of relapse from a phase 3 Study of response-based therapy for intermediate-risk Hodgkin lymphoma (AHOD0031): A report from the Children's Oncology Group","volume":"92","author":"Dharmarajan","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.10.152_bib0019","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1093\/annonc\/mdx287","article-title":"Consolidative proton therapy after chemotherapy for patients with Hodgkin lymphoma","volume":"28","author":"Hoppe","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2021.10.152_bib0020","first-page":"82","article-title":"A randomized phase III trial of brentuximab vedotin (Bv) for de novo high-risk classical hodgkin lymphoma (cHL) in children and adolescents - study design and incorporation of secondary endpoints in Children's Oncology Group (COG) AHOD1331","volume":"232","author":"Castellino","year":"2020","journal-title":"Klin Padiatr"},{"key":"10.1016\/j.ijrobp.2021.10.152_bib0021","doi-asserted-by":"crossref","first-page":"9198","DOI":"10.1200\/JCO.2005.02.907","article-title":"ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: Final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi","volume":"23","author":"Gobbi","year":"2005","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301621030753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301621030753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:58:42Z","timestamp":1759744722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301621030753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0360301621030753"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2021.10.152","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology Group","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2021.10.152","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}